New hope for lung cancer: experimental drug combo enters trial
NCT ID NCT07609251
First seen May 28, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This study tests a new drug called SCTB41 combined with the chemotherapy docetaxel in 90 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination is safe and works better than docetaxel alone. Participants will receive the drugs by IV every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SCTB41 (an experimental drug) combined with docetaxel (a chemotherapy drug)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced lung cancer who have already tried other therapies.
What could go wrong
This is an early phase II study with only 90 participants, so results are preliminary. The combination may cause significant side effects, and there is no guarantee it will be more effective than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.